Journal of Drugs in Dermatology articles from June 2006

Journal of Drugs in Dermatology archives from June 2006

A letter from the guest editors.
June 1, 2006... It gives us great pleasure to present this special issue of the Journal of Drugs in Dermatology by members and alumni of the Department of Dermatology at Henry Ford Hospital in Detroit, Michigan. [ILLUSTRATION OMITTED] [ILLUSTRATION...

About the Henry Ford Health System.
June 1, 2006... Henry Ford Health System is one of the nation's premier health care organizations, combining renowned clinical expertise with education and research and caring for more than 2.5 million patients annually. [ILLUSTRATION OMITTED] From...

How Clarence S. Livingood and his Manual of Dermatology influenced dermatologic therapy.
June 1, 2006... Abstract Clarence S. Livingood and his mentors, Pillsbury and Sulzberger, wrote the Manual of Dermatology, a book that was the dermatologic handbook of choice for thousands of medical officers in World War II. By virtue of its wide...

Intralesional bleomycin for warts: a review.
June 1, 2006... Abstract Intralesional bleomycin has been used for the treatment of warts since the 1970s. Currently, there is a limited amount of evidence from randomized placebo-controlled trials comparing intralesional bleomycin with other local...

Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis.
June 1, 2006... Abstract Psoriasis is a common skin condition affecting approximately 2.6% of the population in the US. The most effective current therapies for psoriasis have suppressive activity against T lymphocytes directly or by modulating the...

Immune protection, natural products, and skin cancer: is there anything new under the sun?
June 1, 2006... Abstract Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human neoplasms, representing one third of all new malignancies diagnosed in the US. The number of new cases diagnosed...

Cytokines in dermatology.
June 1, 2006... Abstract Cytokines are polypeptides that are produced by various cell types and act in an autocrine or paracrine manner. They have many different biological actions and have been used in dermatology to treat a wide range of dermatologic...

Clobetasol propionate for psoriasis: are ointments really more potent?
June 1, 2006... Abstract Background: Clobetasol propionate is the most common topical therapy used for psoriasis in the US. Conventional dermatologic wisdom is that ointment preparations provide the highest potency (due to their occlusive nature and...

Plasmapheresis for refractory urticarial vasculitis in a patient with B-cell chronic lymphocytic leukemia.(CASE REPORTS)
June 1, 2006... Abstract Background: Urticarial vasculitis is a form of cutaneous leukocytoclastic vasculitis clinically characterized by persistent and often painful urticarial lesions. Numerous systemic diseases have been associated with urticarial...

Etanercept for chronic progressive cutaneous sarcoidosis.(CASE REPORTS)
June 1, 2006... Abstract Sarcoidosis is a chronic, multisystem, granulomatous disease that has various cutaneous manifestations. Chronic cutaneous sarcoidosis can be difficult to manage. Patients often need systemic corticosteroids as well as other...

Excess salt and pepper hair treated with a combination of laser hair removal and topical eflornithine HCl.(CASE REPORTS)
June 1, 2006... Abstract A common problem among aging women, salt and pepper facial hair poses a significant psychosocial impact as well as a challenge for treatment. Various laser therapies or topical eflornithine HCl 13.9% cream are commonly used to...

Life-threatening pustular and erythrodermic psoriasis responding to infliximab.(CASE REPORTS)
June 1, 2006... Abstract Pustular and erythrodermic psoriasis can be a debilitating and recalcitrant disease which may result in secondary complications such as sepsis, electrolyte imbalance, renal failure, and heart failure. We report a case of a...

The use of 308-nm excimer laser for dermatoses: experience with 34 patients.(CASE REPORTS)
June 1, 2006... Abstract Targeted phototherapy has been utilized in the past few years for the treatment of various dermatoses. In this article, we summarize the experience of using 308-nm excimer laser at Henry Ford Hospital, Detroit, MI, for the...

Henry Ford Hospital dermatology experience with Levulan Kerastick and blue light photodynamic therapy.(CASE REPORTS)
June 1, 2006... Abstract Photodynamic therapy (PDT) takes advantage of our understanding of the cutaneous response to topically applied porphyrins to selectively destroy malignant or premalignant cells. This type of therapy has been used to treat a...

Furosemide-induced bullous pemphigoid: case report and review of literature.(CASE REPORTS)
June 1, 2006... Abstract Bullous pemphigoid (BP) is an acquired autoimmune disease characterized by subepidermal vesicles and bullae. The etiology for BP is mostly idiopathic with the highest occurrence in elderly patients; however, it is now...

Does folic acid impact the efficacy of methotrexate in the treatment of psoriasis?(WASHINGTON WHISPERS)
June 1, 2006... Does Folic Acid Impact the Efficacy of Methotrexate in the Treatment of Psoriasis? Commentary on: Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Salim...

Phototherapy: a promising approach to localized scleroderma.(WASHINGTON WHISPERS)
June 1, 2006... Phototherapy: A Promising Approach to Localized Scleroderma Commentary on: A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. Kreuter A, et al. J...

Effectiveness of azathioprine combination therapy for atopic dermatitis.(WASHINGTON WHISPERS)
June 1, 2006... Effectiveness of Azathioprine Combination Therapy for Atopic Dermatitis Commentary on: Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial....

Phase I trial begins for CHIR-265, a new melanoma drug.(PIPELINE PREVIEWS)
June 1, 2006... Chiron Corporation recently announced the initiation of Phase I trials for CHIR-265 for the treatment of patients with melanoma. CHIR-265 selectively inhibits Raf kinases, including mutant B-Raf, which has been implicated in the pathogenesis of...

New topical treatment for psoriasis to be available in August 2006.(PIPELINE PREVIEWS)
June 1, 2006... Apollo Pharmaceutical, Inc, announced that Relieva, its topical treatment for psoriasis, will be available in the US in August 2006. Relieva cream is derived from the Mahonia aquifolium plant. This plant is rich in isoquinolone alkaloids which...

Cervarix studies continue to show promise.(PIPELINE PREVIEWS)
June 1, 2006... GlaxoSmithKline's vaccine for cervical cancer prevention, Cervarix, demonstrated 100% efficacy against the development of precancerous lesions due to HPV types 16 and 18 in a 4.5-year follow-up study. HPV types 16 and 18 are responsible for 70%...

Avugane Phase II trials promising for the topical treatment of acne vulgaris.(PIPELINE PREVIEWS)
June 1, 2006... Topotarget A/S recently announced promising results of Phase II trials evaluating the safety and efficacy of Avugane in the topical treatment of acne vulgaris. Avugane is a histone deacetylase inhibitor (HDAC). HDAC inhibitors are transcription...

Randomized controlled study to evaluate CellCept in the treatment of pemphigus vulgaris.(PIPELINE PREVIEWS)
June 1, 2006... Aspreva Pharmaceuticals Corporation is currently working to provide more evidence-based medicines for less common diseases. The company recently announced the initiation of a Phase III trial to evaluate the safety and efficacy of CellCept...

Successful completion of Phase I trial for anthrax antibody.(PIPELINE PREVIEWS)
June 1, 2006... Elusys Therapeutics, Inc, recently announced the successful completion of a Phase I clinical trial for Anthim, an anthrax antibody therapeutic. This study assessed both safety and tolerability of Anthim in healthy volunteers over 42 days. There...

Isotechnika ances positive data from 48-week extension trial of ISA247 for psoriasis.(PIPELINE PREVIEWS)
June 1, 2006... Preliminary data from the 48-week extension trial of ISA247, Isotechnika, Inc's immunosuppressive drug for the treatment of psoriasis, has shown promising results. The patients who completed the 24-week Phase II SPIRIT trial were given the...

FDA approves ANDA for generic fexofenadine.(PIPELINE PREVIEWS)
June 1, 2006... Dr. Reddy's Laboratories in Hyderabad, India and Mylan Laboratories, Inc, in Pittsburg, Pennsylvania recently announced that the FDA has approved their Abbreviated New Drug Applications (ANDA) to manufacture fexofenadine tablets 30 mg, 60mg,...

Cynosure's Cynergy laser gains FDA approval for new indications.(PIPELINE PREVIEWS)
June 1, 2006... Cynosure, Inc, recently announced that the FDA has approved its 585-nm pulse dye laser for the treatment of pigmented lesions including freckles, solar lentigines, cafe au lait macules, and scars and warts. The pulse dye laser already has...

Schools of Pharmacology.
June 1, 2006... Schools of Pharmacology is a periodic feature that will explicate the dermatologic uses and side effects of new medications and devices. It follows medications mentioned in the Pipeline Previews into their approval and use in clinical practice....

Ceftobiprole in the treatment of resistant staphylococcus aureus skin and skin structure infections.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Johnson & Johnson Pharmaceutical Research & Development, LLC. The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in...

Effect of chlorhexidine skin cleansing on skin flora.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Johns Hopkins Bloomberg School of Public Health. Given the potential of skin cleansing with chlorhexidine as a safe, feasible, and cost-effective intervention for reducing...

Comparison of telavancin and vancomycin for complicated skin and skin structure infections with a focus on methicillin-resistant staphylococcus aureus (ATLAS 2).(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Theravance. Study 0018 compares the safety and effectiveness of an investigational drug, telavancin, for the treatment of complicated skin and skin structure infections. ...

Comparison of telavancin and vancomycin for complicated skin and skin structure infections with a focus on methicillin-resistant staphylococcus aureus (ATLAS 1).(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Theravance. Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin...

T4N5 liposomal lotion in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Cancer Institute (NCI). sponsors and collaborators: University of Alabama and NCI. Chemoprevention therapy is the use of certain drugs to try to prevent the development of or...

Photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Cancer Institute (NCI). Sponsors and collaborators: Case Comprehensive Cancer Center and NCI. Photodynamic therapy uses a drug that becomes active when it is exposed to a certain...

Celecoxib in preventing skin cancer.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Cancer Institute (NCI). Sponsors and collaborators: Herbert Irving Comprehensive Cancer Center and National Cancer Institute (NCI). Celecoxib may be effective in preventing skin...

Gefitinib in treating patients who are undergoing surgery and/or radiation therapy for locally advanced or recurrent squamous cell skin cancer.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Cancer Institute (NCI). Sponsors and collaborators: M.D. Anderson Cancer Center and NCI. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for...

Study evaluating sirolimus in non-melanoma skin cancer in kidney transplant recipients.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Wyeth. The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients. ...

Tumorapa 1: efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Hospices Civils de Lyon. In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of...

Study of cetuximab in squamous cell carcinoma of the skin expressing EGFR.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by Centre Hospitalier of Chartres. Sponsors and collaborators: Centre Hospitalier of Chartres and Hospital of Chartres--France. The purpose of this study is to determine whether cetuximab is...

Daptomycin in the treatment of patients with renal insufficiency and complicated skin and skin structure infections.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Cubist Pharmaceuticals. This is a phase IV, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous...

Skin structure infections with suspected or proven MRSA.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Pfizer. To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects. Condition ...

Photodynamic therapy in treating patients with skin cancer.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Cancer Institute (NCI). Sponsors and collaborators: Roswell Park Cancer Institute and NCI. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to...

Study evaluating etanercept on skin and joint disease in psoriatic arthritis.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Wyeth. To assess the efficacy of 2 different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint...

The effects of microdermabrasion on skin remodeling.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by University of Michigan. This research project aims to study the effects of microdermabrasion, a technique causing minimal injury used to improve the appearance of fine...

A study of RO4908463 in hospitalized patients with skin and skin structure infections.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Hoffmann-La Roche. This study will compare the efficacy and safety of RO4908463 (750 mg or 1500 mg iv q8h) with that of "standard care" [PRP (nafcillin or flucloxacillin) or...

Neuroskin Forte for dry skin relief in eczema and psoriasis.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by University of Medicine and Dentistry New Jersey. Sponsors and collaborators: University of Medicine and Dentistry New Jersey and AVVAA World Healthcare Products, Inc. The purpose is to...

Hematopoietic stem cell support in patients with autoimmune bullous skin disorders.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Northwestern University. Autoimmune bullous skin disorders are believed to be due to immune cells, cells that normally protect the body and are now causing damage. This...

Topical agent for treatment of red skin.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Mayo Clinic. SR-01 may reduce facial redness. It is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess...

Phase III safety and efficacy study of I.V. iclaprim vs. linezolid in cSSSI (ASSIST-1).(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Arpida AG. This is a multi-center, investigator-blind, comparative Phase III study. Patients will receive either iclaprim or linezolid for 10 to 14 days. Patients will be...

Fexofenadine in pruritic skin disease.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Sanofi-Aventis. Primary objective: To compare the efficacy and safety profile of Allegra 180 mg tablets plus prednicarbate (2.5 mg/g) vs. prednicarbate (2.5 mg/g) alone in...

Atopic dermatitis-like skin disease in pediatric heart transplant patients.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by University of Minnesota. Sponsored by Maria K. Hordinsky, MD. The skin disease found in pediatric heart transplant patients represents an atopic dermatitis-like rash that is refractory to...

Narrowband UVB light therapy to patients with both light and dark skin types who have 10% of their body involved with psoriasis vulgaris.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by Rockefeller University. This study offers narrowband UVB light therapy to patients with both light and dark skin types who have 10% of their body involved with psoriasis...

Ultraviolet B (UVB) light therapy in the treatment of skin conditions with altered dermal matrix.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by University of Michigan. This research study will evaluate the effectiveness of high-dose UVB light therapy in the treatment of keloid (or hypertrophic scar), scleroderma,...

Common allergens in skin tests for adult atopic dermatitis.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by National Taiwan University Hospital. To analyze the common allergens revealed by skin tests in adult atopic dermatitis patients Condition Atopic Dermatitis ...

Examination of clinical and laboratory abnormalities in patients with defective DNA repair: xeroderma pigmentosum, Cockayne syndrome, or trichothiodystrophy.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Institutes of Health Clinical Center (CC). Sponsored by: National Cancer Institute (NCI). Four rare genetic diseases--xeroderma pigmentosum (XP), Cockayne syndrome (CS), the...

Leprosy skin test trial.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified and sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The purpose of the study is to evaluate the safety of the leprosy skin test antigens, MLSA-LAM and MLCwA, to...

Phase II randomized study of cultured skin substitutes versus split thickness skin grafts in patients with severe burn injuries.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by FDA Office of Orphan Products Development. Sponsors and collaborators: FDA Office of Orphan Products Development and University of Cincinnati. Objectives: To determine the safety and...

Treatment of cutaneous ulcers with a novel biological dressing.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by and sponsored Centre Hospitalier Affilie, Universitaire de Quebec. The aim of the study is to evaluate the effect of a biological dressing on the healing process of venous ulcers. The...

Screening patients for NCI protocol eligibility.(CLINICAL TRIAL REVIEW)
June 1, 2006... This study is currently recruiting patients. Verified by National Institutes of Health Clinical Center (CC). Sponsored by: National Cancer Institute (NCI). The purpose of this protocol is to provide patients with adequate informed consent to...